First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Vanucizumab is an investigational antiangiogenic, first-in-class, bispecific mAb targeting VEGF-A and angiopoietin-2 (Ang-2). This first-in-human study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of vanucizumab in adults with advanced solid tumors refractory to s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2018-04, Vol.24 (7), p.1536-1545
Hauptverfasser:	Hidalgo, Manuel, Martinez-Garcia, Maria, Le Tourneau, Christophe, Massard, Christophe, Garralda, Elena, Boni, Valentina, Taus, Alvaro, Albanell, Joan, Sablin, Marie-Paule, Alt, Marie, Bahleda, Ratislav, Varga, Andrea, Boetsch, Christophe, Franjkovic, Izolda, Heil, Florian, Lahr, Angelika, Lechner, Katharina, Morel, Anthony, Nayak, Tapan, Rossomanno, Simona, Smart, Kevin, Stubenrauch, Kay, Krieter, Oliver
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adults Aged Angiogenesis Angiogenesis Inhibitors - pharmacokinetics Angiogenesis Inhibitors - pharmacology Angiopoietin Antiangiogenics Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Anticancer properties Antitumor activity Asthenia Bayesian analysis Cancer Colon Colon cancer Colonic Neoplasms - drug therapy Colonic Neoplasms - metabolism Design standards Dose-Response Relationship, Drug Drug Administration Schedule Experimental design Female Headache Hemorrhage Humans Hypertension Intravenous administration Kidney Neoplasms - drug therapy Kidney Neoplasms - metabolism Magnetic resonance imaging Male Maximum Tolerated Dose Middle Aged Monoclonal antibodies Neovascularization, Pathologic - drug therapy Overdose Patients Pharmacodynamics Pharmacokinetics Pharmacology Plasma levels Regression models Renal cell carcinoma Safety Solid tumors Toxicity Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors Vesicular Transport Proteins - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!